“Interim data from its phase I study showed all 9 patients received at least 1 cycle of SQ-3370; non-clinical and clinical pharmacokinetics data were consistent, demonstrated more than 50 times higher exposure of doxorubicin in tumor vs. plasma; no dose-limiting toxicities; 5 out of 8 evaluable patients had a best response of stable disease, including patients who progressed on prior doxorubicin or other prior systemic therapies; maximum tolerated dose not yet been reached; dose escalation is ongoing.”
